Correlation Between Changes in the Serum Magnesium Concentration and Visceral Fat Volume in Patients With Type 2 Diabetes Receiving Luseogliflozin: A Sub-Analysis of Data From the LIGHT Study

Tatsuo Yanagawa, Hideshi Matsuda, Masahiro Sugawara, Masahiro Fukuda, Takashi Sasaki

Abstract


Background: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have been reported to more effectively suppress cardiovascular events (CVEs) in patients with type 2 diabetes. The underlying mechanism, however, remains unknown. SGLT-2 inhibitors have the unique beneficial effect of ameliorating hypomagnesemia, which is a well-known independent risk factor for CVE. However, the mechanism by which SGLT-2 inhibitors increase the serum magnesium (Mg) levels also remains unknown. We hypothesized that SGLT-2 inhibitor-induced visceral fat loss might also be correlated with the serum Mg levels.

Methods: We conducted a sub-analysis of the data of 31 patients with type 2 diabetes who were treated with luseogliflozin in the LIGHT study. The correlations between changes in the serum Mg concentration (Delta Mg) and the baseline patient characteristics/changes in the values of clinical parameters at 24 weeks were analyzed by multiple regression analysis.

Results: The Delta Mg was significantly associated with the baseline serum Mg concentration (beta = -0.47, 95% confidence interval (CI): -0.84 - -0.13; P = 0.01) and Delta visceral fat volume (VFV) (beta = -0.33, -0.59 - -0.09; P = 0.03).

Conclusions: We found that elevation of serum Mg concentrations after SGLT-2 inhibitor treatment was associated with two factors; low serum Mg concentrations before the start of treatment and decrease in the VFV after treatment.




J Endocrinol Metab. 2021;11(2):35-41
doi: https://doi.org/10.14740/jem738

Keywords


Type 2 diabetes; SGLT-2 inhibitors; Visceral fat; Magnesium; Cardiovascular events; Metabolic syndrome; Obesity

Full Text: HTML PDF
 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.